Apposite Capital-backed NIMGenetics completed the acquisition of Gene Predictis.

Apposite Capital-backed NIMGenetics, a science-lead genetic diagnostic company, developing and distributing genetic diagnostic tests, completed the acquisition of Gene Predictis, a Swiss precision medicine company. Financial terms were not disclosed. “We are delighted that NIM has completed this acquisition. This demonstrates that NIM is an attractive platform for market consolidation, adding partner firms – aligned with our high-quality products and service delivery – to the group, supporting rapid growth of local provision,” Anne-Laure Meynier, Apposite Capital Investment Director.